Clinical Trials

130 enrolled

Rectal Neoplasms

NCT07394387 2026-05-15

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

58 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07584018 2026-05-13

The DoHAICs Study Expansion Phase

90 enrolled

Carcinoma, Hepatocellular

NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

33 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT03607539 2026-05-11

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3 Completed

397 enrolled 15 charts

Phase 2 Active not recruiting

Lung Neoplasms

NCT06431685 2026-05-08

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Phase 1 Recruiting

10 enrolled

CNS

Meningeal Carcinomatosis

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT06050317 2026-05-01

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT07560488 2026-05-01

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

43 enrolled

Carcinoma, Hepatocellular

NCT05357846 2026-04-30

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07309952 2026-04-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06356584 2026-04-28

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT06204094 2026-04-24

CASINOs

37 enrolled

Rectal Neoplasms

NCT07521852 2026-04-22

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

40 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT03872661 2026-04-21

NIBCUN

36 enrolled

Lung Neoplasms

NCT06860490 2026-04-21

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

164 enrolled

Carcinoma, Hepatocellular

NCT07535632 2026-04-17

BEST

58 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

400 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07537972 2026-04-17

Denosumab Strategy for Liver Cancer With Bone Metastases

50 enrolled

Carcinoma, Hepatocellular

NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Phase 2/3 Recruiting

680 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

100 enrolled

Carcinoma, Hepatocellular

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

49 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07455617 2026-04-06

Study of ABO2102 in KRAS-Mutated Solid Tumors

Phase 1 Recruiting

101 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT04512534 2026-04-02

Sincerely20

51 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular

NCT05427487 2026-03-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

70 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07492342 2026-03-25

K-NADIR

30 enrolled

Resectable NSCLC

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

276 enrolled

Stomach Neoplasms

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3 Completed

344 enrolled

Carcinoma, Hepatocellular

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

430 enrolled

Colorectal Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

49 enrolled

Rectal Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Colonic Neoplasms

NCT06530251 2026-03-04

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Recruiting

280 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular

NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

Phase 2 Completed

10 enrolled 9 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

446 enrolled

Colorectal Neoplasms

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Phase NA Recruiting

28 enrolled

Pancreatic Neoplasms

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

37 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07371611 2026-01-28

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

104 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

30 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Phase 2 Completed

25 enrolled

Cholangiocarcinoma

NCT07120698 2026-01-05

CTONG 2508

115 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07306663 2025-12-29

ESO-Nanjing7

242 enrolled